Indirubin derivatives are potent and selective anti-Trypanosoma cruzi agents

Area of Science:

• Medicinal Chemistry
• Parasitology
• Drug Discovery

Background:

• Current Chagas disease treatments are inadequate, necessitating novel antiparasitic compounds.
• Indirubins, known ATP kinase inhibitors, have shown inhibitory activity against related kinetoplastids like Leishmania.
• This study explores indirubin analogues as potential agents against Trypanosoma cruzi.

Purpose of the Study:

• To evaluate the antiparasitic activity of a series of indirubin analogues against Trypanosoma cruzi.
• To investigate the mechanism of action and in vivo efficacy of promising compounds.
• To identify potential lead compounds for Chagas disease drug development.

Main Methods:

• Screening of 69 indirubin analogues against T. cruzi trypomastigotes and intracellular amastigotes.
• Cell death analysis using electron microscopy and flow cytometry for selected compounds.
• In vivo efficacy testing in a mouse model of Chagas disease for the most potent compounds.

Main Results:

• Seven indirubin analogues exhibited potent T. cruzi inhibitory activity in the low μM and nM ranges.
• Distinct modes of action were observed between different indirubin substitution patterns.
• Compound 11 (3'piperazine-6-BIO) showed the best in vivo efficacy, reducing mortality and parasitaemia at a lower dose than benznidazole.

Conclusions:

• Indirubin analogues represent a promising class of compounds for Chagas disease treatment.
• Compound 11 (3'piperazine-6-BIO) demonstrates significant potential as a lead compound for developing new Chagas disease therapies.
• Further research into indirubin derivatives could yield effective treatments for this life-threatening illness.